# A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Source: https://onco.cc/trials/himalayas-1/  
OnCo record `himalayas-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Rinzimetostat in prostate cancer, now recruiting.

## Summary

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) is a phase 3 interventional study registered as NCT07723248, led by ORIC Pharmaceuticals with Bayer, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1). Planned enrolment is 600 participants (estimated). The study started in 2026-08-03 and primary completion is expected in 2028-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: Himalayas-1
- Tags: ctgov-ingest
- Registry id: NCT07723248
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)
- Sponsor: ORIC Pharmaceuticals
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07723248: https://clinicaltrials.gov/study/NCT07723248

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Rinzimetostat](https://onco.cc/drugs/rinzimetostat/)
- companies: [ORIC Pharmaceuticals](https://onco.cc/companies/oric-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/himalayas-1.json